Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Sandstrom

Pediatric Endocrinology Oxnard, CA Medical Doctor

NPI 1043382856 CMS profile 183977

2000 Outlet Center Dr, Suite 110, Oxnard, CA 93036

Open in the dashboard

General payments

$4,833

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Sandstrom of Oxnard, CA is reported in the CMS Open Payments database as having received $4,833 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,029 32
2024 General $1,118 46
2023 General $776 35
2022 General $1,263 30
2021 General $342 16
2020 General $271 13
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Sandstrom
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Anna Sandstrom were reported at $1,029. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Anna Sandstrom Pediatric Endocrinology median Middle half National median
2019 $34 $196 $68–$845 $163
2020 $271 $124 $37–$722 $114
2021 $342 $134 $35–$691 $132
2022 $1,263 $177 $47–$726 $149
2023 $776 $236 $75–$887 $160
2024 $1,118 $259 $91–$979 $164
2025 $1,029 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ascendis Pharma, Inc. $480 15 payments
  2. Tandem Diabetes Care, Inc. $378 5 payments
  3. Insulet Corporation $371 13 payments
  4. CutisPharma, Inc. $301 14 payments
  5. Neurocrine Biosciences, Inc. $273 5 payments
  6. Dexcom, Inc. $271 12 payments
  7. Tolmar, Inc. $270 14 payments
  8. Medtronic, Inc. $264 4 payments
  9. Arbor Pharmaceuticals, Inc. $252 10 payments
  10. Xeris Pharmaceuticals, Inc. $221 11 payments
  11. Other $1,752 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,786 172 payments
  2. Education $47 2 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $480 15 payments
  2. Triptodur $419 18 payments
  3. t:slim X2 Insulin Pump with Control-IQ $378 5 payments
  4. Omnipod $351 12 payments
  5. Dexcom G6 Transmitter $248 11 payments
  6. CRENESSITY $243 4 payments
  7. FENSOLVI $226 12 payments
  8. Sogroya $209 8 payments
  9. TWIIST $202 3 payments
  10. TZIELD $176 3 payments
  11. Other $1,667 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record